We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
Gilead Sciences partners with LEO Pharma to develop STAT6-based therapies for inflammatory diseases, aiming to enhance patient care with new treatment options.
Biogen plans to acquire Sage Therapeutics, boosting Sage's stock by 34%. This move underscores key market shifts in pharmaceuticals.
Virta Health reports a 60% revenue increase in 2024 by providing nutrition programs as an alternative to costly drugs, appealing to employers focused on sustainable solutions.
Walgreens reports better-than-expected earnings with strategic moves boosting sales, despite net losses and ongoing challenges.
Walgreens Boots Alliance faces analyst skepticism ahead of its earnings report, with mixed ratings and potential acquisition talks casting uncertainty over its stock performance.
Novo Nordisk shares rise post-UBS upgrade, reflecting positive sentiment in the weight-loss drug market despite recent challenges.
Roche enhances its biopharmaceutical capabilities with the acquisition of Poseida Therapeutics, securing a stronger position in the gene therapy market.
Johnson & Johnson's new lung cancer regimen, Rybrevant and Lazcluze, shows a notable survival advantage over AstraZeneca's Tagrisso, sparking hope for better patient outcomes.
Neumora Therapeutics' shares drop as navacaprant fails in a critical depression drug trial amid hopes for a successful outcome.
The 2025 weight-loss drug market faces challenges with competition and supply constraints, impacting key players like Novo Nordisk and Amgen, as indicated by recent data and expert insights.
Learn about FDA's approval of an injectable version of Opdivo, offering a more convenient cancer treatment option.
Novo Nordisk's shares plummet after CagriSema weight-loss drug trials fall short, impacting the company's market position significantly.
117
